论文部分内容阅读
肺水肿(PE)、肺出血(PH)是多种危重疾病常见的临床危重现象,各科均可发生,尤多见于新生儿期。在败血症、肺部感染、硬肿症、新生儿或成人呼吸窘迫综合征(MRDS或ARDS)、窒息、呼吸衰竭等均可发生,死亡率极高。其发病机理未完全明确,可能与血管通渗性变化、凝血功能障碍、心功能不全、免疫机制、体内活性介质、自由基对肺或血管等损害有关。在近年国外及我院在国内首例应用肺表面活性物质(PS)抢救NRDS及ARDS取得成功基础上,以及我院应用活血化瘀方法预防实验动物PE、PH有效的
Pulmonary edema (PE), pulmonary hemorrhage (PH) is a common clinical critically ill phenomenon of many critically ill diseases, all subjects may occur, especially in the neonatal period. In sepsis, lung infections, scleredema, neonatal or adult respiratory distress syndrome (MRDS or ARDS), asphyxia, respiratory failure can occur, the mortality rate is extremely high. Its pathogenesis is not completely clear, may be related to vascular permeability changes, coagulation disorders, cardiac insufficiency, immune mechanisms, the body of active mediators, free radicals on the lungs or blood vessels and other damage related. In recent years, foreign countries and our hospital in the country’s first application of pulmonary surfactant (PS) to rescue the success of NRDS and ARDS based on the success, and our hospital application of blood circulation to prevent experimental animals, PE, PH effective